Download any of the PDFs below to keep important information about CABLIVI and aTTP on hand.
CABLIVI Patient Brochure
Information about CABLIVI for you and your family to download and save.
Download the patient brochure >
CABLIVI Administration Training Guide
Information to help with the administration of CABLIVI.
Download the administration training guide >
CABLIVI Doctor Discussion Guide
Suggested questions to ask your doctor about treatment with CABLIVI.
Download the doctor discussion guide >
CABLIVI Patient Solutions
Learn more about the support offered through CABLIVI Patient Solutions.
Download the CABLIVI Patient Solutions brochure >
The Language of aTTP
Save a list of common terms and definitions to easily reference in conversations with your healthcare team and family.
Download the Language of aTTP >
CABLIVI Patient Solutions Enrollment Form
Enroll in CABLIVI Patient Solutions for specialty pharmacy services, administration training, financial assistance, and more.
Download enrollment form >There are a number of organizations dedicated to providing information and support to people living with aTTP.
National Organization for Rare Disorders
(NORD) >
The Platelet Disorder Support Association >
Note that the opinions expressed by the organizations above do not necessarily reflect the views of Sanofi Genzyme. Sanofi Genzyme does not maintain and is not responsible for the content of communications for the listed organizations or their websites. This is not intended to be a comprehensive list of aTTP disease support organizations. These listings do not constitute an endorsement by Sanofi Genzyme of information provided by any other organizations.
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
